跳至主要内容
临床试验/CTRI/2026/02/102705
CTRI/2026/02/102705尚未招募不适用

A Randomized Controlled Trial Comparing the Efficacy and Safety of Cholecalciferol versus Calcitriol in CKD-MBD Patients with Vitamin D deficiency.

PGIMER1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2026年2月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
PGIMER
入组人数
66
试验地点
1

研究概览

简要总结

Despite widespread use of both cholecalciferol and calcitriol in managing vitamin D

deficiency among patients with Chronic Kidney Disease-Mineral and Bone Disorder

(CKDMBD), there is a lack of robust randomized controlled trials (RCTs) directly comparing

their efficacy and safety. Particularly, limited data are available regarding their effect on

vitamin D

metabolites and bone-specific biochemical markers in this patient population. This evidence

gap hinders clinical decision-making in choosing the optimal form of vitamin D therapy in

CKD-MBD.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • CKD Stage 3 to 5 (not on dialysis) Serum 25(OH) D levels less than 20ng/mL Clinical or biochemical evidence of CKD-MBD.

排除标准

  • Serum calcium more than 10.5 mg/dL Serum iPTH less than 15 pg/mL History of parathyroidectomy Presence of bone diseases unrelated to CKD (e.g., multiple myeloma, bone metastases) Use of immunosuppressive drugs Diagnosed immune-mediated disorders (e.g., systemic lupus erythematosus, sarcoidosis) Critically ill or moribund patients Malabsorption syndrome Sepsis Malignancy Pregnancy or lactation Patients unable to take oral medications Patients not providing consent.

研究者

发起方
PGIMER
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Aman Chaudhary

PGIMER Chandigarh

研究点 (1)

Loading locations...

相似试验